nicoelnino-shutterstock-com

NicoElNino / Shutterstock.com

13 August 2015Americas

Profit is at the heart of every IPR, says Kyle Bass

Hedge fund manager Kyle Bass has fired a response to a motion filed by biotechnology company Celgene seeking to sanction him over “abusive” patent challenges, stating that profit motive is at the centre of every inter partes review (IPR) filing.

Already registered?

Login to your account

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Celgene calls for Kyle Bass sanctions

31 July 2015 Pharmaceutical company Celgene has requested that the US Patent and Trademark Office sanctions hedge fund manager Kyle Bass and his company the Coalition for Affordable Drugs, arguing that the inter partes review petitions he has filed are “abusive” and a “tool to affect the stock prices of public companies”.

USPTO rejects Celgene bid for Bass sanctions

28 September 2015 The US Patent and Trademark Office has rejected a request by biopharmaceutical company Celgene to sanction hedge fund manager Kyle Bass and his organisation the Coalition for Affordable Drugs.

More on this story

Celgene calls for Kyle Bass sanctions

31 July 2015 Pharmaceutical company Celgene has requested that the US Patent and Trademark Office sanctions hedge fund manager Kyle Bass and his company the Coalition for Affordable Drugs, arguing that the inter partes review petitions he has filed are “abusive” and a “tool to affect the stock prices of public companies”.

USPTO rejects Celgene bid for Bass sanctions

28 September 2015 The US Patent and Trademark Office has rejected a request by biopharmaceutical company Celgene to sanction hedge fund manager Kyle Bass and his organisation the Coalition for Affordable Drugs.

More on this story

Celgene calls for Kyle Bass sanctions

31 July 2015 Pharmaceutical company Celgene has requested that the US Patent and Trademark Office sanctions hedge fund manager Kyle Bass and his company the Coalition for Affordable Drugs, arguing that the inter partes review petitions he has filed are “abusive” and a “tool to affect the stock prices of public companies”.

USPTO rejects Celgene bid for Bass sanctions

28 September 2015 The US Patent and Trademark Office has rejected a request by biopharmaceutical company Celgene to sanction hedge fund manager Kyle Bass and his organisation the Coalition for Affordable Drugs.

More features

Bayer gains exclusive licence for heart drug in Japan

EPO delivers key Novo Nordisk, GSK and Inhibrx rulings

McGuireWoods expands team with ex-Novo Nordisk GC

Paul, Weiss swoops for senior duo from Weil, Gotshal

UPC bans Meril Life Sciences from selling infringing heart valve

SCOTUS denies Alvogen unit's appeal to sell Bausch Xifaxan generic

Kathi Vidal to rejoin previous firm as partner following USPTO departure

GSK triumphs in EPO appeal, revoking Pfizer patent